טוען...
New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base
Three-month long-acting paliperidone is a new, recently marketed, formulation of paliperidone, characterised by the longest available dosing interval among long-acting antipsychotics. The clinical profile of 3-month long-acting paliperidone was recently summarised by the European Medicines Agency (E...
שמור ב:
| הוצא לאור ב: | Epidemiol Psychiatr Sci |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Cambridge University Press
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6998643/ https://ncbi.nlm.nih.gov/pubmed/28004623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1017/S2045796016001025 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|